The month of August was replete with clinical trial news and biosimilar launches for the treatment of rheumatic conditions.
August proved to be a big month for biosimilars used to treat patients with rheumatic diseases. Several products were launched around the world, and there were important clinical trial developments. The following is a summary of this news.
Biosimilar Launches for Rheumatoid Arthritis
In Canada, Sandoz launched 2 biosimilars. Its rituximab molecule (Riximyo) is a monoclonal antibody used to treat rheumatoid arthritis (RA), non-Hodgkin lymphoma, and chronic lymphocytic leukemia. The other biosimilar was a pegfilgrastim (Ziextenzo), used to decrease the risks of infection associated with febrile neutropenia in chemotherapy treatment.
Later in the month, British Columbia moved forward with the third phase of its mandatory biosimilar switching program. Patients enrolled in the pharmaCare prescription plan receiving reference rituximab (Rituxan) would be switched to 1 of 3 biosimilar versions available, including Truxima, Riximyo, and Ruxience, according to the plan.
The current program phase will affect patients undergoing treatment for granulomatosis with polyangiitis, microscopic polyangiitis, relapsing-remitting multiple sclerosis, and RA.
Over in Germany, Mylan and Lupin Limited launched their etanercept biosimilar (Nepexto) as part of a commercialization agreement signed in 2018.
The launch comes after Nepexto was approved by the European Commission in May for all indications of the reference product (Enbrel), including RA, juvenile idiopathic arthritis, psoriatic arthritis, axial spondyloarthritis, plaque psoriasis, and chronic severe plaque psoriasis.
Cadila Pharmaceuticals launched its adalimumab biosimilar Cadalimab on the Indian market, marking the company’s fourth product launch since July. Cadila noted that the adalimumab market in India is large: Roughly 7 million individuals have RA, and 2.8% of the population have psoriasis.
Osteoporosis News
In addition, Cadila launched its teriparatide molecule (NuPTH) in India. This drug references Eli Lilly’s Forteo for the treatment of patients with osteoporosis or an increased risk of fracture. Cadila said that India is considered the “osteoporosis capital of the world” because an estimated 26 million individuals have this condition.
Celltrion Healthcare is working to bring a treatment for osteoporosis to market. In September, the company will start a phase 1 clinical trial for a denosumab biosimilar (CT-P41). CT-P41 references Amgen’s Prolia and inhibits the bone resorption process by binding with the cytokine receptor activator of nuclear factor kappa-Β ligand (RANKL). This blocks the development of osteoclasts, which break down bone tissue. Celltrion said it plans to begin phase 3 trials in the first half of 2021 and commercialize the product in 2025 once patents expire for Prolia.
Additionally, Celltrion has partnered with Intract Pharma to produce the world’s first oral infliximab formulation for the treatment of inflammatory bowel disease.
Notable Study Findings
A study from Iran demonstrated the effectiveness of a CinnaGen’s interferon beta-1a biosimilar (ReciGen) in helping to reduce symptoms and achieve virological clearance in patients hospitalized with coronavirus disease 2019 (COVID-19).
ReciGen was tested in combination with Iran’s conventional COVID-19 therapy including hydroxychloroquine and lopinavir/ritonavir and helped resolve COVID-related fever after 8 days in all 20 patients included in the study.
Lastly, investigators doing a year-long real-world study on anti—tumor necrosis factor (TNF) originator biologics and biosimilars for Crohn disease (CD) and ulcerative colitis (UC) found anti-TNF therapy to be more effective for achieving remission in patients with CD compared with those with UC.
The investigators concluded that their study advanced understanding of anti-TNF agents in inflammatory bowel disease and recommended that large prospective studies and randomized controlled trials be done to compare use of biologics in UC versus CD.
Julie Reed: Why 2024 Is Important for Biosimilars
April 17th 2024Julie Reed, executive director of the Biosimilars Forum, showcases how the biosimilar industry is expected to develop throughout 2024, including major policy changes and hope for continued improvement in market share for adalimumab biosimilars.
Decoding the Patent Puzzle: Navigating the Legal Landscape of Biosimilars
March 17th 2024On this episode of Not So Different, Ha Kung Wong, JD, an intellectual patent attorney and partner at Venable LLP, details the confusing landscape that is the US patent system and how it can be improved to help companies overcome barriers to biosimilar competition.
Alvotech’s Stelara Biosimilar, Selarsdi, Receives FDA Approval
April 16th 2024Alvotech’s Selarsdi (ustekinumab-aekn), a biosimilar referencing Stelara (ustekinumab), gained FDA approval, making it the second ustekinumab biosimilar and second for the company to be given the green light for the American market.
Biosimilars Rheumatology Roundup for February 2024—Podcast Edition
March 3rd 2024On this episode of Not So Different, The Center for Biosimilars® revisited all the major rheumatology biosimilar news from February 2024, including the FDA approval of the 10th adalimumab biosimilar, the promise for an oral delivery system for ustekinumab, and the impact of adalimumab products on COVID-19 antibodies.
Biosimilars Council: PBM Rebate Schemes Cost Americans, Payers $6 Billion
April 10th 2024A report from the Biosimilars Council evaluating IQVIA data found that rebate schemes orchestrated by pharmacy benefit managers (PBMs) are costing US patients and payers billions of dollars by suppressing biosimilar adoption.